Charles Schwab Investment Management Inc Revance Therapeutics, Inc. Transaction History

Charles Schwab Investment Management Inc

  • $515 Billion
  • Q3 2024

A detailed history of Charles Schwab Investment Management Inc transactions in Revance Therapeutics, Inc. stock. As of the latest transaction made, Charles Schwab Investment Management Inc holds 790,837 shares of RVNC stock, worth $2.03 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
790,837
Previous 749,587 5.5%
Holding current value
$2.03 Million
Previous $1.93 Million 5.5%
% of portfolio
0.0%
Previous 0.0%

Shares

29 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024
BUY
$2.57 - $2.57 $106,012 - $106,012
41,250 Added 5.5%
790,837 $2.03 Million
Q2 2024

Aug 12, 2024
BUY
$2.34 - $4.73 $115,916 - $234,310
49,537 Added 7.08%
749,587 $1.93 Million
Q1 2024

May 08, 2024
BUY
$4.65 - $9.31 $105,489 - $211,206
22,686 Added 3.35%
700,050 $3.44 Million
Q4 2023

Feb 06, 2024
BUY
$5.81 - $11.2 $80,329 - $154,851
13,826 Added 2.08%
677,364 $5.95 Million
Q3 2023

Nov 08, 2023
BUY
$11.47 - $25.07 $418,574 - $914,879
36,493 Added 5.82%
663,538 $7.61 Million
Q2 2023

Aug 09, 2023
BUY
$24.7 - $37.61 $486,837 - $741,293
19,710 Added 3.25%
627,045 $15.9 Million
Q1 2023

May 11, 2023
BUY
$18.36 - $35.27 $13,164 - $25,288
717 Added 0.12%
607,335 $19.6 Million
Q4 2022

Feb 13, 2023
BUY
$18.32 - $30.66 $697,240 - $1.17 Million
38,059 Added 6.69%
606,618 $11.2 Million
Q3 2022

Nov 14, 2022
BUY
$14.33 - $28.47 $1.24 Million - $2.47 Million
86,844 Added 18.03%
568,559 $15.4 Million
Q2 2022

Aug 15, 2022
SELL
$11.52 - $20.4 $112,285 - $198,838
-9,747 Reduced 1.98%
481,715 $6.66 Million
Q1 2022

May 13, 2022
BUY
$12.36 - $20.31 $180,925 - $297,297
14,638 Added 3.07%
491,462 $9.58 Million
Q4 2021

Feb 11, 2022
BUY
$12.46 - $27.87 $69,240 - $154,873
5,557 Added 1.18%
476,824 $7.78 Million
Q3 2021

Nov 16, 2021
BUY
$25.78 - $33.21 $78,783 - $101,489
3,056 Added 0.65%
471,267 $13.1 Million
Q2 2021

Aug 16, 2021
BUY
$26.8 - $31.84 $570,036 - $677,236
21,270 Added 4.76%
468,211 $13.9 Million
Q1 2021

May 17, 2021
BUY
$24.03 - $29.97 $862,917 - $1.08 Million
35,910 Added 8.74%
446,941 $12.5 Million
Q4 2020

Feb 16, 2021
BUY
$23.41 - $28.34 $121,006 - $146,489
5,169 Added 1.27%
411,031 $11.6 Million
Q3 2020

Nov 13, 2020
BUY
$23.23 - $34.3 $1.62 Million - $2.4 Million
69,842 Added 20.79%
405,862 $10.2 Million
Q2 2020

Aug 14, 2020
BUY
$12.6 - $26.55 $388,659 - $818,961
30,846 Added 10.11%
336,020 $8.21 Million
Q1 2020

May 15, 2020
BUY
$12.46 - $27.81 $446,254 - $996,015
35,815 Added 13.3%
305,174 $4.52 Million
Q4 2019

Feb 07, 2020
BUY
$11.66 - $20.15 $283,034 - $489,121
24,274 Added 9.9%
269,359 $4.37 Million
Q3 2019

Nov 08, 2019
BUY
$10.22 - $14.5 $23,720 - $33,654
2,321 Added 0.96%
245,085 $3.19 Million
Q2 2019

Aug 09, 2019
BUY
$10.67 - $15.49 $185,476 - $269,262
17,383 Added 7.71%
242,764 $3.15 Million
Q1 2019

May 14, 2019
BUY
$15.4 - $20.39 $744,636 - $985,917
48,353 Added 27.31%
225,381 $3.55 Million
Q4 2018

Feb 14, 2019
SELL
$18.06 - $24.96 $16,217 - $22,414
-898 Reduced 0.5%
177,028 $3.56 Million
Q3 2018

Nov 13, 2018
BUY
$23.55 - $30.1 $591,835 - $756,443
25,131 Added 16.45%
177,926 $4.42 Million
Q2 2018

Aug 08, 2018
BUY
$27.45 - $33.35 $499,013 - $606,269
18,179 Added 13.5%
152,795 $4.2 Million
Q1 2018

May 07, 2018
BUY
$29.15 - $37.4 $475,349 - $609,881
16,307 Added 13.78%
134,616 $4.15 Million
Q4 2017

Jan 17, 2018
BUY
$24.55 - $36.3 $25,802 - $38,151
1,051 Added 0.9%
118,309 $4.23 Million
Q3 2017

Nov 13, 2017
BUY
$22.55 - $28.1 $2.64 Million - $3.29 Million
117,258
117,258 $3.23 Million

Others Institutions Holding RVNC

# of Institutions
234
Shares Held
82.8M
Call Options Held
680K
Put Options Held
896K
View Full List

About Revance Therapeutics, Inc.

RVNC Quotes by TradingView
  • Ticker RVNC
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 82,305,696
  • Market Cap $212M
  • Description
  • Revance Therapeutics, Inc., a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug candidate is DaxibotulinumtoxinA for injection, which has completed phase III clinical trials fo...
More about RVNC
Track This Portfolio

Track Charles Schwab Investment Management Inc Portfolio

Follow Charles Schwab Investment Management Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Charles Schwab Investment Management Inc, based on Form 13F filings with the SEC.

News

Stay updated on Charles Schwab Investment Management Inc with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email